915 abstracts found.



Results filter

KU-0059436 plus radiation as first line therapy for glioblastoma multiforme: rationale and phase I clinical trial protocol

Year:

Session type:

Fiona Dungey1, Dana Loeser1, Anthony Chalmers2

1Genome Damage and Stability Centre, University of Sussex, Brighton, UK, 2Brighton and Sussex Medical School, Brighton, UK


Developing nano-particle resonance imaging for use in breast cancer

Year:

Session type:

Mi Wang, Val Speirs, Peng Guan

University of Leeds, Leeds, UK


In vitro and in vivo evaluation of a novel 18F-labeled isatin as an apoptosis PET imaging tracer

Year:

Session type:

Quang-De Nguyen1, Graham Smith1, Meg Perumal1, Matthias Glaser2, Euan A. Stronach3, Hani Gabra3, Eric O. Aboagye1

1Molecular Therapy Group, Imperial College London, London, UK, 2Hammersmith Imanet Limited, London, UK, 3Ovarian Cancer Action (HHMT) Research Unit and Section of Molecular Therapeutics, Imperial College, London, UK


Moving UK breast radiotherapy forward in the IMPORT LOW trial – enabling safe change of practice through quality assurance (QA)

Year:

Session type:

Yat Tsang1, Laura Ciurlionis1, IMPORT Trial Management Group2

1Mount Vernon Hospital, Northwood, Middlesex, UK, 2National Health Service (NHS), National, UK


Imaging the biological activity of AKT-kinase-platinum drug combinations in vivo

Year:

Session type:

Meg Perumal, Quang-De Nguyen, Julius Leyton, Graham Smith, Euan Stronach, Hani Gabra, Eric Aboagye

Molecular Therapy/PET imaging, Imperial College, London, UK


Using hyperpolarised helium-3 MRI to detect changes in ventilation after lung radiotherapy

Year:

Session type:

Omar Din, Jim Wild, Neil Woodhouse, James Swinscoe, Robert Ireland, Matthew Hatton

Weston Park Hospital, Sheffield, UK


Treatment of disseminated melanoma with 211At-methylene blue

Year:

Session type:

Eva Link

London, UK


Apparent diffusion coefficient histogram parameters distinguish paediatric brain tumours

Year:

Session type:

Jonathan Bull, Martin King, Dawn Saunders, Chris Clark

UCL Institute of Child Health, London, UK


Does acute gastrointestinal toxicity during radical pelvic radiotherapy predict late gastrointestinal toxicity? A study using the IBDQ and a Vaizey score, more sensitive measures of radiotherapy-induced toxicity than the RTOG or LENT SOM scales

Year:

Session type:

Jervoise Andreyev, Karen Thomas, Amyn Lalji, Peter Blake, Vincent Khoo, Diana Tait

Royal Marsden Hospital, London, UK


Inter-lesional variability of DCE-MRI response and changes in cardiac output following infusion of the vascular disruptive agent Combretastatin-A4-Phosphate (CA4P)

Year:

Session type:

Andrew Gaya1, N. Jane Taylor2, Tarun Mittal3, J James Stirling2, James d'Arcy4, D Koh4, Gordon Rustin1, Tim Meyer5, Paul Nathan1, David Collins4, Anwar Padhani2

1Mount Vernon Hospital, Northwood, Middlesex, UK, 2Paul Strickland Scanner Centre, Northwood, Middlesex, UK, 3Dept. Imaging, Harefield Hospital, Harefield, Middlesex, UK, 4CR-UK Imaging Group, Institute of Cancer Research, Sutton, Surrey, UK, 5Dept Medical Oncology, Royal Free Hospital, London,, UK


Developing new PET tracers and studying them with new techniques

Year:

Session type:

Martin Christlieb, Robert King

University of Oxford, Oxford, UK


Gene expression following ionising radiation: Identification of biomarkers for dose estimation and prediction of individual response

Year:

Session type:

Sylwia Dziwura1, Alan Mackay2, Paul Finnon1, Simon Bouffler1, Christophe Badie1

1Health Protection Agency, Chilton, Didcot, Oxfordshire, UK, 2The breakthrough Breast Cancer Research centre at the Institute of Cancer Research, London, UK


Temporal evolution and duration of anti-vascular properties of bevacizumab in metastatic colorectal carcinoma (CRC): evaluation by DCE-MRI and tumour volumetrics

Year:

Session type:

James O'Connor1, Geoff Parker1, Andrew Clamp2, Alan Jackson1, Chris Rose1, Claire Mitchell2, Yvonne Watson1, Sue Cheung1, Giovanni Buonaccorsi1, Lynn Hope2, Paula Thorton2, Caleb Roberts1, Olivia del Puerto3, Jurgees Hasan2, Gordon Jayson2

1Imaging Science and Biomedical Engineering, University of Manchester, Manchester, UK, 2CR-UK Department of Medical Oncology, Christie Hospital NHS Trust, Manchester, UK, 3Roche Products Limited, Welwyn Garden City, UK


Abstract withdrawn

Year:

Session type:


Automated [11C]acetate synthesizer – simple way to reliable GMP compliant manufacture of prostate cancer PET imaging radiotracer

Year:

Session type:

Dmitry Soloviev2, Jozef Comor3, Gerd Beyer4, Franklin Aigbirhio1

1Wolfson Brain Imaging Centre, Cambridge University, Cambridge, UK, 2Cambridge Research Institute, Cancer Research UK, Cambridge, UK, 3Vinca Institute, Belgrade, Serbia, 4Isotope Technologies Dresden GmbH (ITD), Dresden, Germany


Endogenous Prostate Apoptosis Response-4 (Par-4) inhibits in vitro growth and motility of prostate cancer cells

Year:

Session type:

Lin Ye, Malcolm Mason, Wen G. Jiang

Cardiff University School of Medicine, Cardiff, UK


Computer modelling of prostate gland deformation for image-guided biopsy and cancer therapies

Year:

Session type:

Dean Barratt1, Yipeng Hu1, Dominic Morgan1, Hashim Ahmed1, Doug Pendse1, Mahua Sahu1, Clare Allen2, David Hawkes1, Mark Emberton1

1University College London, London, UK, 2University College Hospital, London, UK


Mechanisms of androgen receptor activation in advanced prostate cancer: differential coactivator recruitment and gene expression

Year:

Session type:

Greg Brooke, Malcolm Parker, Charlotte Bevan

Imperial College, London, UK


Upper gastrointestinal cancer laparoscopy and endoluminal ultrasound staging audit across five cancer networks

Year:

Session type:

Diana Bailey, Mark Vipond

South West Public Health Observatory, Salisbury, UK


The effect of knockdown of ROCK II on the in vitro invasion and motility of PC3 prostate cancer cells

Year:

Session type:

Jane Lane, Tracey Amanda Martin, Wen Jiang

Cardiff University, Cardiff, UK


An association study of TGFB1 gene variants with post-radiotherapy breast shrinkage: preliminary results of the RAPPER study

Year:

Session type:

Gillian C. Barnett1, Neil G. Burnet1, Charlotte E. Coles1, Caroline Baynes2, Serena Scollen2, Paul D.P. Pharoah2, Elliott Rebecca3, Catharine M.L. West3, Patricia Harrington2, Jennifer Wilkinson1, Margaret Moody1, Carol McQuade1, Gordon C. Wishart1, Alison M. Dunning2

1Addenbrooke's Hospital, Cambridge, UK, 2Strangeways Research Laboratory, Cambridge, UK, 3University of Manchester, Manchester, UK


The role of Sox9 in prostate development and cancer

Year:

Session type:

Martin K. Thomsen, Amanda Swain

Section of Gene Function and Regulation, Institute of Cancer Research, London, UK


IMPORT HIGH: introduction of image guided breast radiotherapy via a national breast trial

Year:

Session type:

Jenny Titley1, Judith Bliss1, Charlotte Coles2, Ellen Donovan2, Philip Evans1, Jo Haviland1, Mark Sydenham1, John Yarnold1, IMPORT Trial Management Group3

1Institute of Cancer Research, Sutton, UK, 2Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK, 3NHS, National, UK


Intrinsic markers of tumour hypoxia and angiogenesis in localised prostate cancer with respect to the outcome of radical treatment

Year:

Session type:

Roy Vergis1, Catherine Corbishley2, Andrew Norman1, Jaclyn Bartlett1, Sameer Jhavar1, Michael Borre4, Sara Heeboll4, Alan Horwich1, Robert Huddart1, Vincent Khoo3, Ros Eeles1, Colin Cooper1, Matthew Sydes5, David Dearnaley1, Chris Parker1

1Institute of Cancer Research, Sutton, UK, 2St George's Hospital, Tooting, UK, 3Royal Marsden NHS Foundation Trust, Sutton, UK, 4Aarhus University Hospital, Skejby, Denmark, 5MRC, London, UK


Integration of ERG gene mapping and gene expression profiling identifies distinct categories of human prostate cancer

Year:

Session type:

Sameer Jhava1, Daniel Brewer1, Sandra Edwards1, Zsofia Kote-Jarai10, Gerhardt Attard1, Jeremy Clark1, Penny Flohr1, Alan Thompson3, Matthew Parker1, Ulf-Hakan Stenman4, Tania Marchbank5, Raymond Playford5, Cyril Fisher6, Gyula Kovacs7, Cathy Corbishley8, Andy Norman2, Johann De-Bono2, Anders Bjartell9, Rosalind Eeles10, Colin Cooper1

1Institute of Cancer Research, Male Urological Cancer Research Centre, Molecular Carcinogenesis, Sutton, UK, 2Royal Marsden NHS Foundation Trust, Sutton, UK, 3Department of Academic Urology, The Royal Marsden NHS Trust Foundation Hospital, London, UK, 4Department of Clinical Chemistry, Helsinki University Central Hospital, Helsinki, Finland, 5Institute of Cell and Molecular Science, Barts and The London School of Medicine, London, UK, 6Department of Histopathology, The Royal Marsden NHS Trust Foundation Hospital, London, UK, 7Laboratory of Molecular Oncology, Medical Faculty, Reprecht-Karls-University, Heidelberg, Germany, 8Department of Cellular Pathology, SGHNHSFT, London, UK, 9Department of Urology, University Hospital Malmo, Malmo, Sweden, 10Institute of Cancer Research, Male Urological Cancer Research Centre, Genetics, Sutton, UK


Circulating Tumor Cell (CTC) counts as intermediate endpoints in Castration-Resistant Prostate Cancer (CRPC): a single centre experience

Year:

Session type:

David Olmos1, Gerhart Attard1, Alison Reid1, Joana Moreira2, Juliet Dukes2, Joo Ern Ang1, Hendrik-Tobias Arkenau1, Roger A'Hern2, Emilda Thompson1, Craig Carden1, Chris Parker1, Johann de Bono1

1The Royal Marsden NHS Foundation Trust, Sutton, Surrey, UK, 2The Institute of Cancer Research, Sutton, Surrey, UK


Prostate tumours with PTEN loss detected by fluorescent in situ hybridisation (FISH) have a worse clinical outcome and are enriched for ETS gene alterations

Year:

Session type:

Alison Reid1, Gerhardt Attard1, Jeremy Clark1, Roy Vergis2, Sara Heeboll3, Daniel Brewer1, Chris Parker2, Johann De-Bono2, Michael Borre3, Colin Cooper1

1Institute of Cancer Research, Sutton, Surrey, UK, 2Royal Marsden NHS Foundation Trust, Sutton, Surrey, UK, 3Aarhus University Hospital, Skejby, Denmark


Identification of candidate biomarkers associated with prostate cancer progression using a proteomic 8-plex iTRAQ approach

Year:

Session type:

Adam Glen, Chee S. Gan, Freddie C. Hamdy, Colby L. Eaton, Simon S. Cross, Phillip C. Wright, Ishtiaq Rehman

University of Sheffield, Sheffield, UK


Psychological distress and prostate specific antigen levels in men with and without prostate cancer

Year:

Session type:

Emma Turner1, Athene Lane1, Chris Metcalfe1, Liz Down1, Freddie Hamdy3, David Neal2, Jenny Donovan1, Kavita Vedhara1

1University of Bristol, Bristol, UK, 2University of Cambridge, Cambridge, UK, 3University of Sheffield, Sheffield, UK


Rectal contouring variability in patients treated with radical radiotherapy for prostate carcinoma and its impact on rectum dose-volume histograms: pilot study

Year:

Session type:

Jacqueline Martin, Peter Kirkbride

Weston Park Hospital, Sheffield, UK


Preclinical development strategy for regulatory approval of a Phase I Trial of 99mTc Demobesin-4 (99mTc DB4) for prostate cancer imaging

Year:

Session type:

Steve Colebrook1, Paul Jones1, Karen Owen1, Rob Williams1, Steve Mather2, Norbert Avril2

1Cancer Research UK, Drug Development Office, London, UK, 2St Bartholomew's Hospital, Department of Nuclear Medicine, London, UK


A prospective study of clinically significant fatigue (CSF) after prostate brachytherapy (PB)

Year:

Session type:

Dawn Storey1, Duncan McLaren1, Rita O'Dea1, Sheila Liggat1, Morven Shipway1, John Smyth2, Michael Sharpe2

1Edinburgh Cancer Centre, Edinburgh, Mid Lothian, UK, 2University of Edinburgh Cancer Research Centre, Edinburgh, Mid Lothian, USA


Salvage radiotherapy for biochemical relapse of prostate cancer after prostatectomy

Year:

Session type:

Jacob S Tanguay1, Laura Petit3, Helen Sharman1, Jawaher Ansari1, Nellie Cheah1, Kate Yates2, Naryanan Srihari3, Andrew Stockdale2, Nicholas James1

1University Hospital Birmingham, Birmingham, UK, 2University Hospital Coventry and Warwick, Coventry, UK, 3Royal Shrewsbury Hospital, Shrewsbury, UK


Monitoring prostate cancer progression with Diffusion Weighted Imaging: variability of perfusion and diffusion components of the Apparent Diffusion Coefficient

Year:

Session type:

Veronica Morgan, Sophie Riches, Nicholas vanAs, Christopher Parker, Nandita deSouza

Institute of Cancer and Royal Marsden NHS Foundation Trust, Sutton, UK


High frequency of t(4;6) translocation and 6q15 deletion in prostate cancer

Year:

Session type:

Ling Shan, Sharon James, Rafael Yanez-Munoz, Yong-Jie Lu

Queen Mary college, London, UK


Analysis of factors influencing survival in patients with metastatic hormone-refractory prostate cancer (mHRPC) following GVAX immunotherapy for prostate cancer

Year:

Session type:

David Smith1, Eric Small2, John Corman3, Celestia Higano4, Minh Nguyen5, Thomas Harding5, Karin Jooss5, Dimitrios Chondros5

1University of Michigan, Ann Arbor, MI, USA, 2University of California, San Francisco, CA, USA, 3Virginia Mason Medical Center, Seattle, WA, USA, 4University of Washington, Seattle, WA, USA, 5Cell Genesys Inc., South San Francisco, CA, USA


Improving trial conduct through a new site monitoring and review process (SMART): experience from the ProtecT study

Year:

Session type:

J Athene Lane1, Susan Bonnington2, Teresa Lennon3, Peter Holding7, Amanda Jones4, C Elizabeth Salter5, David Neal6, Freddie Hamdy7

1University of Bristol, Bristol, UK, 2Leicester General Hospital, Leicester, UK, 3Freeman Hospital, Newcastle, UK, 4University Hospital of Wales, Cardiff, UK, 5Bristol Urological Institute, Bristol, UK, 6Addenbrooke's Hospital, Cambridge, UK, 7University of Sheffield, Sheffield, UK


Diethylstilboestrol is active in docetaxel treated androgen independent prostate cancer

Year:

Session type:

Richard Cox, Santhanam Sundar

Nottingham City Hospital, Nottingham, UK


Efficacy of docetaxel re-treatment as second- and third-line chemotherapy in metastatic hormone refractory prostate cancer patients pre-treated with docetaxel

Year:

Session type:

Jawaher Ansari1, Syed Anwer Hussain1, Anjali Zarkar1, Jacob S Tanguay1, Julie Bliss2, John Glaholm1

1University Hospital Birmingham NHS Trust, Birmingham, UK, 2Good Hope Hospital, Birmingham, UK


Source data verification in a multi-centre randomised controlled trial: the ProtecT study

Year:

Session type:

Michael Davis1, Liz Down1, Athene Lane1, Peter Holding2, David Neal3, Freddie Hamdy2, Jenny Donovan1

1University of Bristol, Bristol, UK, 2University of Sheffield, Sheffield, UK, 3University of Cambridge, Cambridge, UK


Combination of finasteride with the chemopreventive agent resveratrol, decreases proliferative capacity of prostate cancer cells at physiologically achievable doses

Year:

Session type:

Lynne Howells, Emma Blake, Karen Brown

University of Leicester, Leicester, UK


NO-sulindac inhibits the hypoxia response of prostate cancer cells via the Akt signalling pathway

Year:

Session type:

Grant Stewart, Jyoti Nanda, Gordon Brown, Antony Riddick, James Ross, Fouad Habib

University of Edinburgh, Edinburgh, UK


A single institution’s experience of over 200 cases of robotic-assisted radical prostatectomy

Year:

Session type:

Naomi Sharma, Nimish Shah, David Neal

Addenbrooke's Hospital, Cambridge, UK


Functional wellbeing and lower-limb skeletal muscle function in prostate cancer patients on androgen deprivation therapy (ADT)

Year:

Session type:

Liam Bourke, Helen Crank, Amanda Daley, Derek Rosario, John Saxton

1Sheffield Hallam University, Sheffield, UK, 2Sheffield Hallam University, Sheffield, UK, 3University of Birmingham, Birmingham, UK, 4University of Sheffield, Sheffield, UK, 5Sheffield Hallam University, Sheffield, UK


Modulation of androgen receptor activity in prostate cancer progression and therapy

Year:

Session type:

Greg Brooke, Deepa Chotai, Alwyn Dart, Simon Gamble, Derek Lavery, Sue Powell, Vikash Reebye, Charlotte Bevan

Imperial College London, London, UK


Development of a stereo image guidance system to assist robotic surgery of prostate cancer using augmented reality

Year:

Session type:

Dongbin Chen, Erik Mayer, Justin Vale, Anne Anstee, Ara Ara Darzi, Guang-Zhong Yang, Eddie Edwards

Imperial College, London, UK


siRNA target selection using machine learning techniques: genes implicated in aggressive prostate cancer

Year:

Session type:

Matthew Parker1, Colin Campbell2, Luke Carrivick2, Colin Cooper1

1The Institute of Cancer Research, Sutton, UK, 2University of Bristol, Bristol, UK


Genetic susceptibility to prostate cancer due to rare mutations in genes in the DNA repair pathway

Year:

Session type:

Zsofia Kote-Jarai1, Sarah Jugurnauth1, Shani Mulholland1, Stephen Edwards1, Michelle Guy1, Daniel Leongamornlert1, Nayanta Sodha1, Lynn O'Brien1, Rosmary Wilkinson1, Audrey Ardern-Jones2, Amanda Hall2, David Dearnaley2, Keneth Muir3, Aritaya Lophatananon3, The UK Genetic Prostate Cancer Study Collaborators1, The British Association of Urological Surgeon's Section of Oncology2, Douglas Easton4, Rosalind Eeles1

1The Institute of Cancer Research, Sutton/Surrey, UK, 2The Royal Marsden NHS Foundation Trust, Sutton/Surrey, UK, 3University of Notthingham, Notthingham, UK, 4CR-UK Genetic Epidemiology Unit, Cambridge, UK


Exposure to sunlight and prostate cancer

Year:

Session type:

Rebecca Gilbert1, Chris Metcalfe1, Steven Oliver3, David Whiteman2, Chris Bain4, Andy Ness5, Richard Martin1

1Department of Social Medicine, University of Bristol, Bristol, UK, 2Division of Population Studies and Human Genetics, Queensland Institute of Medical Research, Queensland, Australia, 3Department of Health Sciences, University of York, Bristol, UK, 4School of Population Health, The University of Queensland, Queensland, Australia, 5Department of Oral and Dental Science and Department of Social Medicine, University of Bristol, Bristol, UK


Modification by ubiquitin, sumo and intrinsic nuclear and nucleolar localisation signals targets lyric to sub-nuclear compartments

Year:

Session type:

Hayley Thirkettle, Jo Girling, Ian Mills, David Neal, Hayley Whitaker

University of Cambridge, Cambridge, UK